CTLA4 and prostate carcinoma: To determine whether expression of the immune checkpoint molecule CTLA-4 could potentially be restraining the vaccine response of prostate/prostate cancer specific cells, we stained the prostate-specific CD8 T cells for CTLA-4 expression.